Kinnov Therapeutics Competitors and Similar CompaniesClear all

Kinnov Therapeutics's competitors and similar companies include AbClon, Upstream Bio, Albert Labs and ONCOtherapeutics.

	Kinnov Therapeutics Kinnov Therapeutics is a company dedicated to the research and development of therapies against addiction.	AbClon AbClon (앱클론(주)) is a developer, manufacturer, and distributor of antibody drugs.	Upstream Bio Upstream Bio is a clinical-stage biotechnology company that develops treatments for inflammatory diseases.	Albert Labs Albert Labs is a clinical research and drug development company.	ONCOtherapeutics ONCOtherapeutics is a contract research organization that runs multiple clinical trials.
Founding Date	Founding Date N/A	Founding Date 2010	Founding Date 2021	Founding Date 2009	Founding Date 2005
Type	Type Private	Type Public	Type Public	Type Public	Type Private
Tags	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare biotech clinical research drug development therapy
Locations	Locations Orléans, FR HQ	Locations KR HQ	Locations Waltham, US HQ	Locations Burnaby, CA HQ Porto, PT Manchester, GB	Locations West Hollywood, US HQ
Employees	Employees N/A	Employees N/A	Employees 38	Employees N/A	Employees 13
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 1.3 b	Valuation ($) 401.7 k	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ₩2.3b (FY, 2024)	Revenue (est.) $2.9m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods (₩74.1m) (FY, 2024)	Cost of goods $23m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ₩2.4b (FY, 2024)	Gross profit ($20.2m) (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income (₩16.3b) (FY, 2024)	Net income ($143.4m) (FY, 2025)	Net income ($7.1m) (FY, 2022)	Net income N/A